To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high-dose conditioning. Engraftment, acute GvHD and severe infections were comparable in both groups. During the observation period, 1/25 patients (4%) after RIC and 14/50 (28%) after standard SCT died due to transplant-related causes; cumulative nonrelapse mortality (NRM) was 4% after RIC and 24% after standard SCT (P ¼ 0.029). In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS). Overall survival (OS) was 40% after RIC and 37% after standard SCT (NS). Stage of disease, cytogenetic risk profile, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS. In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies. Allogeneic SCT after reduced-intensity conditioning (RIC) has resulted in donor cell engraftment, complete remissions and cure in patients with malignant haematologic diseases.
The high nonrelapse morbidity and mortality of allogeneic stem cell transplantation (SCT) has promoted the search for less toxic preparative regimens. Experimental and clinical data have demonstrated that immunosuppression rather than marrow depletion is crucial for donor cell engraftment. 1, 2 Allogeneic SCT after reduced-intensity conditioning (RIC) has resulted in donor cell engraftment, complete remissions and cure in patients with malignant haematologic diseases. [2] [3] [4] A high rate of mixed chimerism (MC) has been observed after RIC. 5 Prolonged MC has been induced by RIC in animal models, 1, 6 but MC is associated with increased risk of graft failure or relapse in humans. 2, 7 Despite a reduction in conditioning intensity, rates of acute GvHD and infections are still high in most studies. [8] [9] [10] [11] [12] However, nonrelapse mortality (NRM) could be reduced in several uncontrolled trials after RIC. 2, 8, [13] [14] [15] [16] Although long-term follow-up data are not available and no prospective study comparing RIC with standard SCT has been published so far, RIC has rapidly become an established modification of allogeneic SCT and RIC now accounts for more than a quarter of all allogeneic SCT in Europe. 17 RIC has only rarely been applied to patients with rapidly proliferating haematologic diseases, because an increased relapse rate is assumed due to the rapid disease kinetics of acute leukaemias and the lower cytotoxic potential of RIC regimens.
In 1998, we initiated a clinical study on RIC in patients with acute leukaemias, who have contraindications to standard high dose conditioning. 7, 18 So far, more than 40 patients have been included and recent analysis showed a NRM below 10% similar to data from the Seattle group, despite high rates of infection and GvHD. 19 In the absence of prospective randomised trials we performed a retrospective analysis to further investigate the proposed beneficial effect of RIC on NRM and to validate relapse risk in these patients. The first 25 patients with acute lymphoblastic leukaemia (ALL) and acute myelogenous leukaemia (AML), who had received RIC, were analysed and compared to a historical control group of patients with ALL and AML who had undergone standard SCT after high-dose radio-chemotherapy at our institution.
Patients and methods
The first 25 consecutive patients with ALL or AML, who had undergone RIC because of contraindications to standard SCT between August 1998 and June 2002 were included to ensure sufficient follow-up time. Contraindications to standard SCT are listed in Table 1 . In total, 11/25 patients had more than one contraindication to standard high-dose conditioning.
By 1 : 2 matching these 25 case patients were matched to a historical control group of 50 patients with ALL or AML. Matching criteria were diagnosis (ALL or AML), stage of disease (1. complete remission (CR-1) or 4CR-1), donor type (HLA -identical related or unrelated donor) and age at transplantation (Table 1) . HLA-typing comprised serologic typing for class I loci A and B and molecular typing for class II loci DRB1 and DQB1. Historical controls were selected from 75 adults with ALL and 70 adults with AML, who had received highdose conditioning and allogeneic SCT between July 1996 and December 2002. None of the 50 controls underwent a second transplant. All 75 patients fulfilled criteria of highrisk acute leukaemia because of high cell count at diagnosis, prolonged time until first complete remission, advanced or refractory disease or cytogenetic aberrations with known unfavourable prognosis. 21, 22 A total of 16/25 case patients and 25/50 patients had refractory or relapsed disease at the time of transplant. Patients were well matched for diagnosis, stage of disease and donor type; RIC patients were slightly older and more of them were transplanted with advanced disease, but differences were not significant (Table 1) .
Preparative regimens
RIC comprised fludarabine 30 mg/m 2 , day À10 until day À5 (total dose 180 mg/m 2 ), busulfan 4 mg/kg, day À6 and day À5 (total dose 8 mg/kg) and antithymocyte globulin (rabbit; ATG, Fresenius, Germany) 10 mg/kg, day À4 until day À1 (total dose 40 mg/kg). 3 Standard conditioning comprised total body irradiation 2 Â 2 Gy, day À6 until day À4 (total dose 12 Gy) and either cyclophosphamide 60 mg/kg, day À3 and day À2 (total dose 120 mg/kg) (n ¼ 36) or cyclophosphamide 100 mg/kg on day À4 plus etoposide 50 mg/kg on day À3 (n ¼ 12) or etoposide alone 50 mg/kg on day À3 (n ¼ 2).
GvHD prophylaxis and therapy
After RIC 22/25 patients received cyclosporine A (CSA) i.v. starting on day À1 until day 60 and tapered afterwards, if no GvHD had developed. Owing to the high GvHD rate observed, tapering of CSA was delayed beyond day 90 during the study and mycophenolate mofetil (MMF) i.v. was added from day À1 to day 28 in three patients. Control patients with a related donor received CSA until day 150-180 plus short-course methotrexate (MTX) i.v. In related donors, prednisone was given instead of MTX, if etoposide was part of the conditioning regimen. After unrelated SCT, GvHD prophylaxis consisted of CSA, MTX and prednisone. Prednisone was tapered off after day 28.
Acute and chronic GvHD were evaluated clinically using established criteria 23, 24 and histologically proven, whenever possible. Acute GvHD was treated with high-dose prednisone; monoclonal chimeric interleukin-2 receptor antibody and ATG was given to refractory patients. Chronic GvHD was treated with CSA and prednisone; refractory chronic GvHD was treated with MMF, cyclophosphamide and extracorporal photopheresis. Survival after RIC is not inferior to standard SCT G Massenkeil et al
Infection prophylaxis
All patients received antimicrobial prophylaxis with ciprofloxacin, oral amphotericin B suspension and acyclovir during bone marrow aplasia. Pneumocystis jroveci prophylaxis was performed with trimethoprime/sulfamethoxazole as first-line or pentamidine inhalation as second-line therapy. CMV-negative blood products were provided for CMV-seronegative recipient-donor constellations. Patients with a history of suspected invasive fungal infection (IFI) and residual organ infiltrates received preemptive antimycotic therapy from the first day of conditioning until stable haematopoietic reconstitution.
Infection surveillance and diagnosis
Sepsis, fever of unknown origin (FUO), and suspected IFI were defined according to the standard definitions 20, 25, 26 and were analysed together as severe infections for statistical purposes. Weekly blood testing for CMV-DNA and -antigenemia was performed until discharge and at days 90, 180 and 360 after transplantation. Preemptive parenteral ganciclovir therapy was initiated as recommended.
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Engraftment and chimerism analysis
Bone marrow was used as the stem cell source in 20 and mobilized peripheral blood in 55 patients. Engraftment was defined as a neutrophil count above 0.5/nl and platelet counts above 20/nl for 3 days without transfusion support. G-CSF was given to all 25 patients after RIC and to 17/50 patients with an unrelated donor after standard SCT to shorten time to neutrophil reconstitution. Chimerism analysis from peripheral blood leukocyte subpopulations or bone marrow were determined by a multiplex shorttandem-repeat (STR) -assay with nine STR systems plus the Amelogenin gene with fluorescence-based detection 1 month, 2, 3, 6 and 12 months after transplantation. 7 Analysis comprised CD 3 þ , CD 4 þ , CD 8 þ , CD 19 þ cells in peripheral blood and CD34 þ cells in bone marrow; residual cells were also analysed. MC was defined as 5% or more recipient cells in at least one leukocyte subpopulation in two independent analyses after haematopoietic reconstitution. 7 Prophylactic donor lymphocyte infusions (DLI) were planned to be given to patients with MC after day 60 or earlier to patients with uncontrolled leukaemia before SCT.
Haematologic, cytogenetic and molecular response of disease was evaluated 1 month, 3, 6, and 12 months after transplantation by bone marrow aspiration. After RIC, engraftment was also assessed 2 weeks after transplantation.
Statistical analysis
Results are given as median and range. Nonparametric statistical tests (Mann-Whitney U-test) were used because of limited samples. Survival data and median survival with 95% confidence limits with respect to NRM, relapsefree ¼ disease-free survival (DFS) and overall survival (OS) in the defined groups were compared univariately for differences with log-rank-statistic. 28 Follow-up maturity to ensure comparable follow-up times of survival curves in two independent groups was controlled. 29 The relationships between conditioning regimens and haematopoietic reconstitution, chimerism status, acute and chronic GvHD, and infections after SCT were evaluated using Fisher's exact test and the exact w 2 test. Cox' proportional hazard regression analysis was performed to evaluate the prognostic value of the interesting variables. 30 Statistical analyses were performed using SPSS 11.0 (Statistical Package for the Social Science) for Windows. Significance was always assessed at the Po0.05 level, two-sided.
Results

Engraftment and chimerism analysis
A total of 22/25 case (88%) and 47/50 control patients (94%) reconstituted. One patient in each group had primary graft failure; two patients in each group had refractory leukaemia. In chimerism analysis at day 30, 13/22 analysed patients (59%) still had MC after RIC and 6/34 patients (18%) after standard SCT (P ¼ 0.002). The respective numbers after 90 days were 3/15 (20%) with MC after RIC and 3/19 (16%) after standard SCT (NS), only patients considered to be in remission were included in the chimerism analysis (Figure 1 ).
DLI were given to 16/25 patients (64%) after RIC and 15/50 patients (30%) after standard SCT because of MC or suspected high relapse risk.
GvHD
Acute GvHD developed in 13/25 patients after RIC and 32/50 after standard SCT (NS ), but acute GvHD grade III-IV was more frequently observed after RIC ( Table 2) . Onset of acute GvHD was notably delayed after RIC with a median of 83 days (range 9-97) as compared to 26 days (8-80) after standard SCT (P ¼ 0.001). Survival after RIC is not inferior to standard SCT G Massenkeil et al
All 13 patients with GvHD after RIC had received DLI. 8/15 patients, who had received DLI after standard SCT developed GvHD.
Infections after transplantation
The number of severe infections was comparable in both groups.
Probable and possible IFI were diagnosed in four patients after RIC and nine patients after standard SCT (NS). All 13 patients had had a history of suspected IFI before transplantation and were therefore regarded as having reactivated or progressive fungal infection ( Table 2 ). In total, 10/25 case patients and 22/50 control patients received antimycotic therapy after transplantation.
Outcome
Follow-up maturity for outcome analysis of NRM, DFS and OS were not significantly different between groups.
Nonrelapse mortality (NRM)
One out of 25 patients (4%) died 3 months after RIC from acute intestinal GvHD and sepsis. A total of 14/50 control patients (28%) died from nonrelapse causes 1-60 months after standard SCT (P ¼ 0.029). Causes of death were infection alone in 5/14 patients, severe GvHD alone in 3/14 patients, and infection plus GvHD in 6/14 patients. One additional patient died 118 days after standard SCT most likely from pulmonary embolism, which was not regarded as transplant-related.
Cumulative 3-year-NRM was 4% after RIC and 24% after standard SCT (P ¼ 0.029) (Figure 2 ). No other variable had significant impact on NRM. Multivariate analysis could not be performed because of limited sample size.
Disease-free survival (DFS)
In total, 15 out of 25 patients (60%) relapsed 3 months (1-37 months) median after RIC and have died. In total, 20/50 controls (40%) relapsed 6 months median (1-32 months) after standard SCT (NS) and 18/20 have died from leukaemia. DFS at 3 years was 43% after RIC and 49% after standard SCT (P ¼ 0.218) (Figure 3) . Stage of disease (P ¼ 0.003), cytogenetic risk (P ¼ 0.001), grade of acute GvHD (P ¼ 0.034), chronic GvHD (P ¼ 0.033) and chimerism status at day 90 (P ¼ 0.002) had significant impact on DFS in univariate analysis. At 3 years DFS for ALL-patients was 51 and 46% for AML-patients (NS). In multivariate analysis, CR-1 (vs 4CR-1) (P ¼ 0.042, HR Table 2 Post-transplantation course after RIC (n ¼ 25) and standard SCT (n ¼ 50) 
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Survival (OS)
After a median follow-up of 49 months (95% CI, 36-63 months) after RIC, 9/25 patients (36%) are alive in CR. A total of 5/9 surviving patients had advanced disease before SCT. After standard SCT, 17 out of 50 patients (34%) are alive at a median follow-up of 65 months (95% CI, 39-91 months), 15/17 are in CR. A total of 7/17 patients had advanced disease before SCT. OS at 3 years was 40% after RIC with a median survival of 13 months (95% CI, 1-33 months) and 37% after standard SCT with a median survival of 21 months (95% CI, 3-38 months), a nonsignificant difference. (P ¼ 0.930) (Figure 4) . Stage of disease (P ¼ 0.005), cytogenetic risk (Po0.001), chronic GvHD (P ¼ 0.005) and severe infections (P ¼ 0.015) were significant risk factors for OS. Limited sample sizes did not allow for strata analysis of, for example, stage of disease vs conditioning regimens. OS at 3 years was 44% in ALL and 34% in AML patients (NS).
On multivariate analysis, only chronic GvHD (vs no chronic GvHD) had significant favourable impact on OS (Po0.001, HR 0.131 (95% CI, 0.060-0.284)).
Discussion
Despite an increasing number of allogeneic SCT after RIC, 17 long-term data comparing outcome with patients after standard SCT are not available. Retrospective analyses have indicated that a reduction in NRM is feasible by RIC. 10, [13] [14] [15] [16] The number of patients with high-risk AML and especially ALL, who have undergone RIC is still small.
In the largest series of patients with ALL we have shown that RIC can cure these patients, if they undergo transplantation early in the course of disease. 18 To our knowledge, our study represents the first observational analysis in patients with acute leukemias comparing RIC to a historical control of patients after standard SCT. Our analysis comprised engraftment, posttransplant infections, GvHD and outcome. We used a 1 : 2 matched-pair design to diminish confounding effects of variables with known effect on NRM and relapse rate. A nonsignificant trend to higher age and advanced disease was observed in patients after RIC compared to historical controls, because advanced age was one criterion for choosing RIC and several patients had already failed prior standard transplantation. However, we were able to demonstrate that, despite more advanced diseases before RIC, outcome after dose reduced conditioning was not inferior to high intensity conditioning in this study population.
Graft failure and refractory leukaemia were rare, which is especially noteworthy, because other groups have reported higher rates of graft failure after RIC, 2,8 which was probably attributable to less intensive immunosuppression. The RIC-regimen employed by us 3 was more intensive than other RIC protocols, 2 but ensured engraftment in these rapidly proliferating diseases. At the same time, a higher number of mixed chimeras underscores the 'nonmyeloablative' character of this regimen.
The reduced intensity of the conditioning regimen, the more frequent use of peripheral blood stem cells and more frequent use of G-CSF after RIC explain the faster neutrophil recovery in these patients.
As recipient immunity is not fully ablated after RIC, MC can intentionally be induced by low intensity conditioning in experimental and clinical studies, which is thought to establish and maintain mutual donor-recipient tolerance. 
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This was confirmed in our own analysis, demonstrating a higher rate of mixed chimera early after RIC as opposed to standard SCT. However, prolonged MC was highly predictive of recurring leukaemia in humans, independent of the conditioning regimen. 2, 7 We therefore strove to convert MC to complete donor chimerism (CC) by prophylactic use of DLI. 7, 31 Outcome analysis of our data confirmed the instability and negative prognostic impact of prolonged MC at day 90 after transplantation.
The expectations of RIC were a reduction in nonrelapse morbidity and mortality, but severe infections and GvHD were encountered at comparable rates in both groups, and severe forms of acute GvHD were even more prevalent after RIC. The high rate of acute and chronic GvHD after RIC can very likely be attributed to the shorter and less intensive GvHD prophylaxis with only one or two drugs after RIC, and the early administration of prophylactic DLI. In fact, acute GvHD after RIC developed after DLI. This might have been caused by the higher rate of MC after RIC than after standard SCT, as shown in Figure 1 . GvHD after DLI frequently resembled acute gut GvHD grade III-IV, thereby explaining the higher rate of severe acute GvHD after RIC. These experiences prompted us to prolong and intensify GvHD prophylaxis and delay the first administration of DLI beyond day 100 after SCT.
High rates of acute GvHD have also been reported by others after RIC alone 2, 5, 8, 21, 32 and after DLI [32] [33] [34] and observational uncontrolled series have seen high rates of viral, bacterial and some fungal infections after RIC as well. [8] [9] [10] 35 Nevertheless, NRM was surprisingly low after RIC, although these unselected patients represented a highrisk group, which would have been considered ineligible for allogeneic SCT a few years ago. The low NRM observed in ALL and AML is in line with outcome after RIC in CML, NHL, MDS, M. Hodgkin, and CLL. 2, 5, 11, [13] [14] [15] [16] We hypothesize that the reduced NRM after RIC could be ascribed to less severe organ damage of RIC. 36 When acute GvHD develops late as described, 12, 37 patients might have recovered from acute conditioning-related organ toxicity; however, this cannot be proven from our data.
The most important concern in applying RIC to acute leukaemias is the suspected increased relapse risk. A prolonged time to full disease response after RIC has been demonstrated in slowly proliferating diseases, 5, 38 which is worrisome, because relapses in uncontrolled acute leukaemias occur early after transplantation. 39 Indeed, a high number of relapses occurred after RIC, but a quarter of these patients had already failed previous standard SCT. The ability of RIC to cure patients with advanced leukaemia is underlined by the fact that 5/9 survivors after RIC were transplanted with uncontrolled disease and have a median follow-up of more than 40 months. Patients with ALL and AML had comparable relapse and survival rates in our analysis.
Although considerably more patients relapsed after RIC, DFS and OS were similar in both groups.
The conditioning regimens had no impact on survival. Rather, established risk factors like stage of disease or karyotype influenced survival. Age and donor type had no significant impact on outcome, confirming that RIC can be offered to patients over 50 years and those with an unrelated donor.
Reports on DFS after RIC from the literature are conflicting with higher relapse rates in patients with CLL, but not in those with Hodgkin's disease and MDS. [13] [14] [15] A compelling argument for a GvL-effect after both conditioning regimens is a lower relapse risk in patients with acute GvHD grade I-II and chronic GvHD as outlined above.
The outcome analysis of our study is consistent with other retrospective analyses, which have observed comparable OS after RIC and high-dose conditioning, [12] [13] [14] [15] although a matched-pair design was rarely chosen by others. 10 It seems that the higher relapse rate after RIC is compensated by a lower NRM in our and other studies, resulting in survival rates similar to outcome after standard conditioning.
OS in case and control patients is comparable to published registry data or large single centre series in acute leukaemias after standard SCT. 39, 40 Methodological limitations of our analysis comprise the retrospective character, the combined analysis of patients with ALL and AML, a higher number of peripheral blood stem cell transplants after RIC, the more frequent applications of G-CSF and DLI after RIC and the intensification of GvHD-prophylaxis during the observational period.
Nevertheless, this retrospective matched analysis suggests that NRM can be considerably reduced by RICregimens in patients with ALL or AML. RIC was equivalent to patients transplanted after conventional high-dose radio-and chemotherapy, although more patients had advanced disease before RIC, demonstrating that long-term leukaemia-free survival can be achieved in these patients. Large prospective studies are urgently needed to elucidate the role of RIC in patients with malignant diseases including those with acute leukaemias.
